XVIVO Perfusion AB
– We empower transplant teams to save more lives
XVIVO Perfusion AB is a medical technology company with headquarter in Gothenburg, Sweden, and office in Denver, USA. We export 98% and have sales in more than 35 countries. We are firmly rooted in medical science and our core business is in ex vivo organ preservation. We are focused on developing optimized solutions for organ, tissue and cell preservation and perfusion in connection with transplantation. We have more than 15 years of experience within the transplant industry and are dedicated to providing more effective, clinically proven and innovative products that both increase the availability of acceptable donor organs and improve survival after transplantation.
Our vision and passion
XVIVO was founded in Gothenburg, Sweden, in 1998 by Dr Magnus Nilsson who had a genuine interest in medical science and a vision that nobody should have to die while waiting for a transplantation.
Driven by his vision he started collaboration and cooperation with scientist and researchers at leading clinics world-wide to find a solution that could help more patients in need. Research and development is still performed in close collaborations with leading transplantation teams and scientists world-wide. We invest 40% of our revenue in preclinical and clinical research collaborations.
Since the start, new committed employees and distributors have joined the company´s mission to developing innovative products and solutions that will ultimately lead to that nobody should have to die waiting for a transplant.
Gold standard in lung preservation
In line with our ambition we introduced Perfadex® in 2000 and the product is the gold standard for lung preservation. Perfadex® was specifically formulated to preserve the function and integrity of organs rich in endothelium during flushing and cold ischemic storage prior to transplantation and reperfusion.
Current problem in lung transplantation – Organ shortage
Since the first successful lung transplantation performed in Toronto 1983, lung transplantation has become a lifesaving procedure for patients suffering from endstage lung diseases. However, there are still major problems to be solved.
The demand for donor lungs has risen constantly over the years, yet the supply of donor lungs has remained unchanged. This supply issue is aggravated by the exceptionally low utilization grade of donated lungs; currently less than 20% of the lungs offered for transplantation are actually utilized.
Over the years there has been an ongoing search for new options to increase the availability of acceptable organ donors. Transplant centres have evaluated different options such as the use of lungs from older donors, lungs donated after cardiac arrest (DCD) and other sub-optimal/marginal lungs currently rejected for use.
EVLP – New technique expanding the pool of acceptable organs
After preclinical and clinical research for lung preservation a new concept for lung transplantation was developed with the aim of reaching a new group of donors (non-heart beating) using a warm perfusion solution, STEEN Solution™, ex vivo.
STEEN Solution™ is a buffered extracellular solution that includes human albumin to provide an optimal colloid osmotic pressure and dextran 40 to coat and protect the endothelium from excessive leucocyte interaction. STEEN Solution™ is designed to facilitate prolonged evaluation and promote stability of isolated lungs ex vivo.
The aim of EVLP is to reproduce the in vivo environment of the donor lung, using ventilation and perfusion. The function of marginal lungs can now be assessed by the normothermic ex vivo lung perfusion (EVLP) technique, thus further expanding the pool of acceptable donor lungs.
The method is now an established clinical routine in most major lung transplant centers in Europe, Canada and Australia and more than 300 transplants have been performed using this technique. EVLP is not only the ideal setting for donor evaluation it also opens up the possibility for lung treatment.
XPS™ – the flexible comprehensive EVLP platform
XVIVO Perfusion System (XPS) is part of our ambition to provide our customers with solutions and systems that can improve the transplant process outcome, facilitate the work for the transplant team and enhance the long-term outcomes and quality of life for the transplant recipient.
The system was developed together with and modified by clinicians with genuine experience and knowledge from normothermic EVLP using STEEN Solution™. Understanding the clinical needs and challenges transplant teams encounter in daily work, XPS facilitates the clinical decision making and offers a flexible comprehensive platform for EVLP.
XPS was developed to provide transplantation teams with a consistent and easy-to-use method of performing EVLP in the hospital. The EVLP team can feel confident that, if needed, they could easily get a second opinion from a colleague; or additional tests may be performed easily within the hospital.
The donor lungs are transported in regular manner, in an ice box from the procurement site. The donor lungs are flushed thoroughly with Perfadex and then put on the EVLP machine. After warming up according to a detailed protocol, it is up to the EVLP team to set preferred ventilation strategy and perfusion strategy depending on each donor lung requirements. Integrated in-line perfusate gas monitors (PGM) enables for real-time trending of pH and pO2 during the entire EVLP procedure. The XPS also enables precise continuous monitoring of EVLP performance metrics, all pre-set by the EVLP team.
XPS is specifically designed for allowing X-ray or CT scan while doing normothermic EVLP. If a mobile unit is not available, XPS may be transported within the hospital as it is built with a long lasting battery. This allows for simultaneous X-ray and CT scan without interrupting the EVLP process.
Research and future therapies
XVIVO Perfusion supports research in the field of ex vivo organ perfusion, EVOP. We currently support worldwide teams in their strive to develop new applications and areas for EVOP. EVOP may in the future provide the opportunity to deliver personalized medicine for organs, i.e. the opportunity to define specific diagnosis and deliver appropriate treatments to a metabolically active organ.
Please join XVIVO Perfusion to fulfill our mission to develop innovative products and solutions that will ultimately lead to the outcome that nobody should have to die waiting for a transplant.